The chief medical officer at Cognito Therapeutics provided a clinical overview on promising findings surrounding the company’s gamma sensory stimulation device in patients with Alzheimer disease. [WATCH TIME: 10 minutes]
Ralph Kern, MD, MHSc
Advertisement
Articles by Ralph Kern, MD, MHSc
The chief medical officer at Cognito Therapeutics talked about a medical device designed to slow cognitive decline in patients with Alzheimer disease through gamma frequency brain stimulation. [WATCH TIME: 6 minutes]
The chief medical officer and chief operating officer of Brainstorm Cell Therapeutics spoke about a host of topics related to the treatment of amyotrophic lateral sclerosis.
Advertisement
Latest Updated Articles
Ralph Kern, MD, MHSc: The State of Therapies for ALSPublished: April 25th 2018 | Updated:
Harnessing Gamma Frequencies to Modulate Alzheimer Pathology: Ralph Kern, MD, MHScPublished: April 15th 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Fenebrutinib Hits Key Phase 3 Marks in Relapsing and Primary Progressive MS
2
FDA Clears Phase 2a Clinical Trial to Test JOTROL in Patients With Parkinson Disease
3
OnabotulinumtoxinA Fails to Meet Primary End Point in Phase 3 PRECLUDE Trial for Episodic Migraine
4
Overviewing Positive Early Data from ACHIEVE Trial of Zeleciment Basivarsen in DM1: Doug Kerr, MD, PhD
5
